Early detection and prognosis evaluation for hepatocellular carcinoma by circulating tumour DNA methylation: A multicentre cohort study

De‐Zhen Guo,Ao Huang,Ying‐Chao Wang,Shuang Zhou,Hui Wang,Xiang‐Lei Xing,Shi‐Yu Zhang,Jian‐Wen Cheng,Ke‐Hui Xie,Qi‐Chang Yang,Cheng‐Cheng Ma,Qing Li,Yan Chen,Zhi‐Xi Su,Jia Fan,Rui Liu,Xiao‐Long Liu,Jian Zhou,Xin‐Rong Yang

DOI: https://doi.org/10.1002/ctm2.1652

IF: 8.554

2024-05-15

Clinical and Translational Medicine

Abstract:The HepaAiQ assay integrates the most effective HCC‐specific methylation biomarkers using multilocus quantitative PCR. In multicentre studies, the HepaAiQ model accurately distinguishes HCC from other liver diseases, surpassing existing serum tests. The HepaAiQ excels in early‐stage HCC detection in high‐risk patients and post‐resection assessment, potentially fulfilling clinical needs with high accuracy, accessibility and affordability. Background Early diagnosis of hepatocellular carcinoma (HCC) can significantly improve patient survival. We aimed to develop a blood‐based assay to aid in the diagnosis, detection and prognostic evaluation of HCC. Methods A three‐phase multicentre study was conducted to screen, optimise and validate HCC‐specific differentially methylated regions (DMRs) using next‐generation sequencing and quantitative methylation‐specific PCR (qMSP). Results Genome‐wide methylation profiling was conducted to identify DMRs distinguishing HCC tumours from peritumoural tissues and healthy plasmas. The twenty most effective DMRs were verified and incorporated into a multilocus qMSP assay (HepaAiQ). The HepaAiQ model was trained to separate 293 HCC patients (Barcelona Clinic Liver Cancer (BCLC) stage 0/A, 224) from 266 controls including chronic hepatitis B (CHB) or liver cirrhosis (LC) (CHB/LC, 96), benign hepatic lesions (BHL, 23), and healthy controls (HC, 147). The model achieved an area under the curve (AUC) of 0.944 with a sensitivity of 86.0% in HCC and a specificity of 92.1% in controls. Blind validation of the HepaAiQ model in a cohort of 523 participants resulted in an AUC of 0.940 with a sensitivity of 84.4% in 205 HCC cases (BCLC stage 0/A, 167) and a specificity of 90.3% in 318 controls (CHB/LC, 100; BHL, 102; HC, 116). When evaluated in an independent test set, the HepaAiQ model exhibited a sensitivity of 70.8% in 65 HCC patients at BCLC stage 0/A and a specificity of 89.5% in 124 patients with CHB/LC. Moreover, HepaAiQ model was assessed in paired pre‐ and postoperative plasma samples from 103 HCC patients and correlated with 2‐year patient outcomes. Patients with high postoperative HepaAiQ score showed a higher recurrence risk (Hazard ratio, 3.33, p

oncology,medicine, research & experimental